Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Jounce Therapeutics regains worldwide rights to JTX-8064 from Bristol-Myers » 08:02
06/04/20
06/04
08:02
06/04/20
08:02
JNCE

Jounce Therapeutics

$5.62 /

+0.1 (+1.81%)

, BMY

Bristol-Myers

$60.21 /

-0.45 (-0.74%)

Jounce Therapeutics…

Jounce Therapeutics (JNCE) announced that it has regained the worldwide rights to JTX-8064 from Bristol Myers Squibb (BMY). JTX-8064 is a highly-selective, potential first-in-class antibody that targets the Leukocyte Immunoglobulin Like Receptor B2 on macrophages, and was licensed to Celgene in July 2019. As part of its Celgene integration process, Bristol Myers Squibb is streamlining its pipeline and addressing areas of overlap. As a result, Bristol Myers Squibb notified Jounce that the JTX-8064 License Agreement is being terminated. In July 2019, Jounce and Celgene, which is now a Bristol Myers Squibb company, announced an exclusive License Agreement for the worldwide rights to JTX-8064. Under the terms of the agreement, Jounce received a $50M non-refundable license fee from Celgene. Effective, June 3, 2020, the License Agreement is terminated. Beyond transition costs and efforts, neither Bristol Myers Squibb or Jounce have any further financial or service obligations to one another. All Jounce intellectual property rights pertaining to JTX-8064 and licensed to Celgene have been reacquired by Jounce.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$5.62 /

+0.1 (+1.81%)

BMY Bristol-Myers
$60.21 /

-0.45 (-0.74%)

JNCE Jounce Therapeutics
$5.62 /

+0.1 (+1.81%)

05/07/20 H.C. Wainwright
Jounce Therapeutics price target lowered to $8 from $10 at H.C. Wainwright
03/25/20 Raymond James
Jounce upgraded to Strong Buy ahead of cancer data at Raymond James
03/25/20 Raymond James
Jounce Therapeutics upgraded to Strong Buy from Outperform at Raymond James
BMY Bristol-Myers
$60.21 /

-0.45 (-0.74%)

06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
JNCE Jounce Therapeutics
$5.62 /

+0.1 (+1.81%)

BMY Bristol-Myers
$60.21 /

-0.45 (-0.74%)

BMY Bristol-Myers
$60.21 /

-0.45 (-0.74%)

BMY Bristol-Myers
$60.21 /

-0.45 (-0.74%)

BMY Bristol-Myers
$60.21 /

-0.45 (-0.74%)

Wednesday
Conference/Events
MyoKardia participates in a conference call with Cantor Fitzgerald » 12:55
06/03/20
06/03
12:55
06/03/20
12:55
MYOK

MyoKardia

$103.23 /

-0.27 (-0.26%)

Conference call with…

Conference call with management will be held on June 3 at 1:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MYOK MyoKardia
$103.23 /

-0.27 (-0.26%)

MYOK MyoKardia
$103.23 /

-0.27 (-0.26%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MYOK MyoKardia
$103.23 /

-0.27 (-0.26%)

MYOK MyoKardia
$103.23 /

-0.27 (-0.26%)

Conference/Events
MyoKardia participates in a conference call with Cantor Fitzgerald » 04:55
06/03/20
06/03
04:55
06/03/20
04:55
MYOK

MyoKardia

$103.50 /

+0.5 (+0.49%)

Conference call with…

Conference call with management will be held on June 3 at 1:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MYOK MyoKardia
$103.50 /

+0.5 (+0.49%)

MYOK MyoKardia
$103.50 /

+0.5 (+0.49%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MYOK MyoKardia
$103.50 /

+0.5 (+0.49%)

MYOK MyoKardia
$103.50 /

+0.5 (+0.49%)

Tuesday
On The Fly
Fly Intel: Wall Street's top stories for Tuesday » 17:00
06/02/20
06/02
17:00
06/02/20
17:00
TIF

Tiffany

$117.04 /

-11.345 (-8.84%)

, SWBI

Smith & Wesson Brands

$15.00 /

+1.43 (+10.54%)

, RGR

Sturm, Ruger

$71.07 /

+2.72 (+3.98%)

, VSTO

Vista Outdoor

$11.45 /

+0.79 (+7.41%)

, WU

Western Union

$23.10 /

+2.35 (+11.33%)

, MGI

MoneyGram

$3.37 /

+0.77 (+29.62%)

, AAPL

Apple

$323.36 /

+1.53 (+0.48%)

, PLNT

Planet Fitness

$73.93 /

+6.32 (+9.35%)

, NLS

Nautilus

$7.19 /

-0.095 (-1.30%)

, PTON

Peloton

$49.05 /

+3.2 (+6.98%)

, W

Wayfair

$188.36 /

+21.36 (+12.79%)

, ARNA

Arena Pharmaceuticals

$68.26 /

+9.56 (+16.29%)

, EVH

Evolent Health

$6.37 /

-0.47 (-6.87%)

, BMY

Bristol-Myers

$60.66 /

+0.35 (+0.58%)

, LVMUY

LVMH

$0.00 /

+ (+0.00%)

Equity markets in the…

Open Full Text

ShowHide Related Items >><<
WU Western Union
$23.10 /

+2.35 (+11.33%)

W Wayfair
$188.36 /

+21.36 (+12.79%)

VSTO Vista Outdoor
$11.45 /

+0.79 (+7.41%)

TIF Tiffany
$117.04 /

-11.345 (-8.84%)

SWBI Smith & Wesson Brands
$15.00 /

+1.43 (+10.54%)

RGR Sturm, Ruger
$71.07 /

+2.72 (+3.98%)

PTON Peloton
$49.05 /

+3.2 (+6.98%)

PLNT Planet Fitness
$73.93 /

+6.32 (+9.35%)

NLS Nautilus
$7.19 /

-0.095 (-1.30%)

MGI MoneyGram
$3.37 /

+0.77 (+29.62%)

LVMUY LVMH
$0.00 /

+ (+0.00%)

EVH Evolent Health
$6.37 /

-0.47 (-6.87%)

BMY Bristol-Myers
$60.66 /

+0.35 (+0.58%)

ARNA Arena Pharmaceuticals
$68.26 /

+9.56 (+16.29%)

AAPL Apple
$323.36 /

+1.53 (+0.48%)

TIF Tiffany
$117.04 /

-11.345 (-8.84%)

06/03/20 Credit Suisse
Tiffany could be worth $60-$75 if LVMH puts 'deal on ice,' says Credit Suisse
12/09/19 Cowen
Tiffany downgraded to Market Perform from Outperform at Cowen
12/06/19
Fly Intel: Top five analyst downgrades
12/06/19 Loop Capital
Tiffany price target raised to $135 from $85 at Loop Capital
SWBI Smith & Wesson Brands
$15.00 /

+1.43 (+10.54%)

06/02/20 Lake Street
Smith & Wesson Brands price target raised to $19 from $11.50 at Lake Street
RGR Sturm, Ruger
$71.07 /

+2.72 (+3.98%)

06/02/20 Lake Street
Sturm, Ruger price target raised to $80 from $68 at Lake Street
06/01/20 KeyBanc
May background check data 'cleared already high bar,' says KeyBanc
03/19/20
Fly Intel: Top five analyst initiations
03/19/20 Lake Street
Sturm, Ruger initiated with a Buy at Lake Street
VSTO Vista Outdoor
$11.45 /

+0.79 (+7.41%)

06/02/20 B. Riley FBR
Vista Outdoor price target raised to $13 from $10 at B. Riley FBR
05/08/20 B. Riley FBR
Vista Outdoor price target lowered to $10 from $14 at B. Riley FBR
03/19/20
Vista Outdoor management to hold virtual meetings with B. Riley FBR
WU Western Union
$23.10 /

+2.35 (+11.33%)

06/02/20 BTIG
Western Union-Money Gram review could note more online competition, says BTIG
04/08/20 Wells Fargo
Western Union downgraded to Underweight from Equal Weight at Wells Fargo
04/06/20 Barclays
Western Union price target lowered to $18 from $25 at Barclays
04/03/20 Northcoast
Northcoast cuts estimates for MoneyGram and Western Union
MGI MoneyGram
$3.37 /

+0.77 (+29.62%)

04/06/20 Barclays
MoneyGram price target lowered to $1 from $2 at Barclays
03/24/20 Northland
Northland downgrades MoneyGram to Market Perform on coronavirus lockdowns
AAPL Apple
$323.36 /

+1.53 (+0.48%)

06/03/20 Morgan Stanley
Apple price target raised to $340 from $326 at Morgan Stanley
06/02/20 Susquehanna
Apple iPhone 12 builds tracking below expectations, says Susquehanna
05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
PLNT Planet Fitness
$73.93 /

+6.32 (+9.35%)

06/02/20 Roth Capital
Planet Fitness price target raised to $70 from $58 at Roth Capital
06/01/20 Jefferies
Planet Fitness traffic trends improving in reopened states, says Jefferies
05/12/20 Roth Capital
Roth Capital downgrades Planet Fitness to Neutral on resumption of coverage
05/12/20 Roth Capital
Planet Fitness assumed Neutral from Buy at Roth Capital
NLS Nautilus
$7.19 /

-0.095 (-1.30%)

06/02/20 SunTrust
Nautilus price target raised to $10 from $8 at SunTrust
05/06/20 Lake Street
Nautilus price target raised to $9 from $7 at Lake Street
04/23/20
Nautilus upgraded to Buy at SunTrust on expected home fitness surge
PTON Peloton
$49.05 /

+3.2 (+6.98%)

05/19/20 SunTrust
Peloton price target raised to $60 from $52 at SunTrust
05/13/20 Rosenblatt
Peloton on track to meet, potentially beat subscriber guidance, says Rosenblatt
05/13/20 JMP Securities
Peloton price target raised to $59 from $53 at JMP Securities
W Wayfair
$188.36 /

+21.36 (+12.79%)

06/02/20 Piper Sandler
Piper Sandler boosts target for 'significantly undervalued' Wayfair to $225
05/18/20 Wedbush
Williams-Sonoma upgraded to Outperform at Wedbush
05/15/20
Fly Intel: Top five analyst downgrades
05/15/20 Citi
Wayfair downgraded to Sell from Neutral at Citi
ARNA Arena Pharmaceuticals
$68.26 /

+9.56 (+16.29%)

06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
EVH Evolent Health
$6.37 /

-0.47 (-6.87%)

06/02/20
Fly Intel: Top five analyst downgrades
06/02/20 Canaccord
Evolent Health price target lowered to $13 from $17 at Canaccord
06/02/20 Cantor Fitzgerald
Evolent Health downgraded to Neutral from Overweight at Cantor Fitzgerald
06/01/20 Cantor Fitzgerald
Evolent Health downgraded to Neutral from Overweight at Cantor Fitzgerald
BMY Bristol-Myers
$60.66 /

+0.35 (+0.58%)

06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
LVMUY LVMH
$0.00 /

+ (+0.00%)

06/03/20 Kepler Cheuvreux
LVMH downgraded to Hold from Buy at Kepler Cheuvreux
05/13/20 UBS
LVMH price target lowered to EUR 397 from EUR 400 at UBS
05/07/20 HSBC
LVMH price target lowered to EUR 440 from EUR 510 at HSBC
WU Western Union
$23.10 /

+2.35 (+11.33%)

W Wayfair
$188.36 /

+21.36 (+12.79%)

VSTO Vista Outdoor
$11.45 /

+0.79 (+7.41%)

TIF Tiffany
$117.04 /

-11.345 (-8.84%)

RGR Sturm, Ruger
$71.07 /

+2.72 (+3.98%)

PTON Peloton
$49.05 /

+3.2 (+6.98%)

PLNT Planet Fitness
$73.93 /

+6.32 (+9.35%)

NLS Nautilus
$7.19 /

-0.095 (-1.30%)

MGI MoneyGram
$3.37 /

+0.77 (+29.62%)

LVMUY LVMH
$0.00 /

+ (+0.00%)

EVH Evolent Health
$6.37 /

-0.47 (-6.87%)

BMY Bristol-Myers
$60.66 /

+0.35 (+0.58%)

ARNA Arena Pharmaceuticals
$68.26 /

+9.56 (+16.29%)

AAPL Apple
$323.36 /

+1.53 (+0.48%)

WU Western Union
$23.10 /

+2.35 (+11.33%)

W Wayfair
$188.36 /

+21.36 (+12.79%)

TIF Tiffany
$117.04 /

-11.345 (-8.84%)

RGR Sturm, Ruger
$71.07 /

+2.72 (+3.98%)

PTON Peloton
$49.05 /

+3.2 (+6.98%)

PLNT Planet Fitness
$73.93 /

+6.32 (+9.35%)

LVMUY LVMH
$0.00 /

+ (+0.00%)

EVH Evolent Health
$6.37 /

-0.47 (-6.87%)

BMY Bristol-Myers
$60.66 /

+0.35 (+0.58%)

AAPL Apple
$323.36 /

+1.53 (+0.48%)

WU Western Union
$23.10 /

+2.35 (+11.33%)

W Wayfair
$188.36 /

+21.36 (+12.79%)

TIF Tiffany
$117.04 /

-11.345 (-8.84%)

SWBI Smith & Wesson Brands
$15.00 /

+1.43 (+10.54%)

PTON Peloton
$49.05 /

+3.2 (+6.98%)

PLNT Planet Fitness
$73.93 /

+6.32 (+9.35%)

NLS Nautilus
$7.19 /

-0.095 (-1.30%)

LVMUY LVMH
$0.00 /

+ (+0.00%)

EVH Evolent Health
$6.37 /

-0.47 (-6.87%)

BMY Bristol-Myers
$60.66 /

+0.35 (+0.58%)

ARNA Arena Pharmaceuticals
$68.26 /

+9.56 (+16.29%)

AAPL Apple
$323.36 /

+1.53 (+0.48%)

WU Western Union
$23.10 /

+2.35 (+11.33%)

W Wayfair
$188.36 /

+21.36 (+12.79%)

TIF Tiffany
$117.04 /

-11.345 (-8.84%)

PTON Peloton
$49.05 /

+3.2 (+6.98%)

PLNT Planet Fitness
$73.93 /

+6.32 (+9.35%)

MGI MoneyGram
$3.37 /

+0.77 (+29.62%)

EVH Evolent Health
$6.37 /

-0.47 (-6.87%)

BMY Bristol-Myers
$60.66 /

+0.35 (+0.58%)

AAPL Apple
$323.36 /

+1.53 (+0.48%)

AAPL Apple
$323.36 /

+1.53 (+0.48%)

On The Fly
Arena jumps after Bristol-Myers' colitis drug meets study endpoints » 13:24
06/02/20
06/02
13:24
06/02/20
13:24
ARNA

Arena Pharmaceuticals

$67.23 /

+8.53 (+14.53%)

, BMY

Bristol-Myers

$60.13 /

-0.18 (-0.30%)

Shares of Arena…

Open Full Text

ShowHide Related Items >><<
BMY Bristol-Myers
$60.13 /

-0.18 (-0.30%)

ARNA Arena Pharmaceuticals
$67.23 /

+8.53 (+14.53%)

ARNA Arena Pharmaceuticals
$67.23 /

+8.53 (+14.53%)

06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
BMY Bristol-Myers
$60.13 /

-0.18 (-0.30%)

06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
BMY Bristol-Myers
$60.13 /

-0.18 (-0.30%)

ARNA Arena Pharmaceuticals
$67.23 /

+8.53 (+14.53%)

BMY Bristol-Myers
$60.13 /

-0.18 (-0.30%)

BMY Bristol-Myers
$60.13 /

-0.18 (-0.30%)

ARNA Arena Pharmaceuticals
$67.23 /

+8.53 (+14.53%)

BMY Bristol-Myers
$60.13 /

-0.18 (-0.30%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:19
06/02/20
06/02
12:19
06/02/20
12:19
AAPL

Apple

$320.10 /

-1.73 (-0.54%)

, RGR

Sturm, Ruger

$72.20 /

+3.85 (+5.63%)

, SWBI

Smith & Wesson Brands

$15.12 /

+1.545 (+11.39%)

, VSTO

Vista Outdoor

$11.43 /

+0.765 (+7.18%)

, W

Wayfair

$187.72 /

+20.72 (+12.41%)

, ARNA

Arena Pharmaceuticals

$67.10 /

+8.4 (+14.31%)

, BMY

Bristol-Myers

$60.06 /

-0.25 (-0.41%)

, LULU

Lululemon

$309.11 /

+0.45 (+0.15%)

, SDRL

Seadrill

$0.37 /

-0.0966 (-20.54%)

Equity markets in the…

Open Full Text

ShowHide Related Items >><<
W Wayfair
$187.72 /

+20.72 (+12.41%)

VSTO Vista Outdoor
$11.43 /

+0.765 (+7.18%)

SWBI Smith & Wesson Brands
$15.12 /

+1.545 (+11.39%)

SDRL Seadrill
$0.37 /

-0.0966 (-20.54%)

RGR Sturm, Ruger
$72.20 /

+3.85 (+5.63%)

LULU Lululemon
$309.11 /

+0.45 (+0.15%)

BMY Bristol-Myers
$60.06 /

-0.25 (-0.41%)

ARNA Arena Pharmaceuticals
$67.10 /

+8.4 (+14.31%)

AAPL Apple
$320.10 /

-1.73 (-0.54%)

AAPL Apple
$320.10 /

-1.73 (-0.54%)

06/02/20 Susquehanna
Apple iPhone 12 builds tracking below expectations, says Susquehanna
05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
05/27/20 Jefferies
Apple price target raised to $370 from $350 at Jefferies
RGR Sturm, Ruger
$72.20 /

+3.85 (+5.63%)

06/02/20 Lake Street
Sturm, Ruger price target raised to $80 from $68 at Lake Street
06/01/20 KeyBanc
May background check data 'cleared already high bar,' says KeyBanc
03/19/20
Fly Intel: Top five analyst initiations
03/19/20 Lake Street
Sturm, Ruger initiated with a Buy at Lake Street
SWBI Smith & Wesson Brands
$15.12 /

+1.545 (+11.39%)

06/02/20 Lake Street
Smith & Wesson Brands price target raised to $19 from $11.50 at Lake Street
VSTO Vista Outdoor
$11.43 /

+0.765 (+7.18%)

06/02/20 B. Riley FBR
Vista Outdoor price target raised to $13 from $10 at B. Riley FBR
05/08/20 B. Riley FBR
Vista Outdoor price target lowered to $10 from $14 at B. Riley FBR
03/19/20
Vista Outdoor management to hold virtual meetings with B. Riley FBR
W Wayfair
$187.72 /

+20.72 (+12.41%)

06/02/20 Piper Sandler
Piper Sandler boosts target for 'significantly undervalued' Wayfair to $225
05/18/20 Wedbush
Williams-Sonoma upgraded to Outperform at Wedbush
05/15/20
Fly Intel: Top five analyst downgrades
05/15/20 Citi
Wayfair downgraded to Sell from Neutral at Citi
ARNA Arena Pharmaceuticals
$67.10 /

+8.4 (+14.31%)

06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
BMY Bristol-Myers
$60.06 /

-0.25 (-0.41%)

06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
LULU Lululemon
$309.11 /

+0.45 (+0.15%)

06/02/20
Fly Intel: Top five analyst downgrades
06/02/20 Wells Fargo
Wells Fargo downgrades Lululemon with shares up 125% since mid-March
06/02/20 Wells Fargo
Lululemon downgraded to Equal Weight from Overweight at Wells Fargo
05/29/20 Raymond James
Lululemon price target raised to $335 from $250 at Raymond James
SDRL Seadrill
$0.37 /

-0.0966 (-20.54%)

05/28/20 Nordea
Seadrill downgraded to Sell from Hold at Nordea
08/13/19
Fly Intel: Top five analyst downgrades
08/13/19 BTIG
Seadrill downgraded to Neutral from Buy at BTIG
W Wayfair
$187.72 /

+20.72 (+12.41%)

VSTO Vista Outdoor
$11.43 /

+0.765 (+7.18%)

SDRL Seadrill
$0.37 /

-0.0966 (-20.54%)

RGR Sturm, Ruger
$72.20 /

+3.85 (+5.63%)

LULU Lululemon
$309.11 /

+0.45 (+0.15%)

BMY Bristol-Myers
$60.06 /

-0.25 (-0.41%)

ARNA Arena Pharmaceuticals
$67.10 /

+8.4 (+14.31%)

AAPL Apple
$320.10 /

-1.73 (-0.54%)

W Wayfair
$187.72 /

+20.72 (+12.41%)

RGR Sturm, Ruger
$72.20 /

+3.85 (+5.63%)

LULU Lululemon
$309.11 /

+0.45 (+0.15%)

BMY Bristol-Myers
$60.06 /

-0.25 (-0.41%)

AAPL Apple
$320.10 /

-1.73 (-0.54%)

W Wayfair
$187.72 /

+20.72 (+12.41%)

VSTO Vista Outdoor
$11.43 /

+0.765 (+7.18%)

RGR Sturm, Ruger
$72.20 /

+3.85 (+5.63%)

LULU Lululemon
$309.11 /

+0.45 (+0.15%)

BMY Bristol-Myers
$60.06 /

-0.25 (-0.41%)

ARNA Arena Pharmaceuticals
$67.10 /

+8.4 (+14.31%)

AAPL Apple
$320.10 /

-1.73 (-0.54%)

W Wayfair
$187.72 /

+20.72 (+12.41%)

LULU Lululemon
$309.11 /

+0.45 (+0.15%)

BMY Bristol-Myers
$60.06 /

-0.25 (-0.41%)

AAPL Apple
$320.10 /

-1.73 (-0.54%)

AAPL Apple
$320.10 /

-1.73 (-0.54%)

Recommendations
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse » 11:44
06/02/20
06/02
11:44
06/02/20
11:44
ARNA

Arena Pharmaceuticals

$68.10 /

+9.4 (+16.01%)

, BMY

Bristol-Myers

$59.88 /

-0.43 (-0.71%)

Credit Suisse analyst…

Credit Suisse analyst Martin Auster raised the firm's price target on Arena Pharmaceuticals (ARNA) to $87 from $77 and keeps an Outperform rating on the shares after Bristol-Myers (BMY) announced that S1P modulator ozanimod met its primary endpoint of clinical remission in the Phase 3 "True North" study of adults with moderate to severe ulcerative colitis. Auster views ozanimod's topline success as de-risking for the S1P class and sees positive read-through for Arena's etrasimod, he tells investors. He has increased his view on the odds of success for etrasimod in ulcerative colitis following Bristol's report, the analyst added.

ShowHide Related Items >><<
BMY Bristol-Myers
$59.88 /

-0.43 (-0.71%)

ARNA Arena Pharmaceuticals
$68.10 /

+9.4 (+16.01%)

ARNA Arena Pharmaceuticals
$68.10 /

+9.4 (+16.01%)

06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
BMY Bristol-Myers
$59.88 /

-0.43 (-0.71%)

06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
BMY Bristol-Myers
$59.88 /

-0.43 (-0.71%)

ARNA Arena Pharmaceuticals
$68.10 /

+9.4 (+16.01%)

BMY Bristol-Myers
$59.88 /

-0.43 (-0.71%)

BMY Bristol-Myers
$59.88 /

-0.43 (-0.71%)

ARNA Arena Pharmaceuticals
$68.10 /

+9.4 (+16.01%)

BMY Bristol-Myers
$59.88 /

-0.43 (-0.71%)

Hot Stocks
Arena jumps 13% after Bristol-Myers reports positive ulcerative colitis data  10:57
06/02/20
06/02
10:57
06/02/20
10:57
ARNA

Arena Pharmaceuticals

$65.70 /

+7 (+11.93%)

, BMY

Bristol-Myers

$60.33 /

+0.02 (+0.03%)

 
ShowHide Related Items >><<
BMY Bristol-Myers
$60.33 /

+0.02 (+0.03%)

ARNA Arena Pharmaceuticals
$65.70 /

+7 (+11.93%)

ARNA Arena Pharmaceuticals
$65.70 /

+7 (+11.93%)

06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
BMY Bristol-Myers
$60.33 /

+0.02 (+0.03%)

06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
BMY Bristol-Myers
$60.33 /

+0.02 (+0.03%)

ARNA Arena Pharmaceuticals
$65.70 /

+7 (+11.93%)

BMY Bristol-Myers
$60.33 /

+0.02 (+0.03%)

BMY Bristol-Myers
$60.33 /

+0.02 (+0.03%)

ARNA Arena Pharmaceuticals
$65.70 /

+7 (+11.93%)

BMY Bristol-Myers
$60.33 /

+0.02 (+0.03%)

Recommendations
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald » 10:57
06/02/20
06/02
10:57
06/02/20
10:57
ARNA

Arena Pharmaceuticals

$65.46 /

+6.76 (+11.52%)

, BMY

Bristol-Myers

$60.31 /

+ (+0.00%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Arena Pharmaceuticals (ARNA) to $88 from $68 and reiterates an Overweight rating on the shares. Bristol Meyers' (BMY) positive topline data this morning from the pivotal study of its sphingosine-1-phosphate ozanimod in ulcerative colitis is a "positive readthrough" to Arena's etrasimod ulcerative colitis program, Young tells investors in a research note. The analyst increased her probability of success 80% from 75% and is now "very confident" in the Phase 3 success of etrasimod. Young also thinks that S1P1 as a class is shaping up to be a "big commercial opportunity" and increased her peak sales to $3B. Arena shares to be up at least 10% today on Bristol's news given that ozanimod and etrasimod are both S1P1s and this is the first positive Phase 3 readout for the class in ulcerative colitis, says the analyst. Arena Pharmaceuticals in morning trading is up 13%, or $7.49, to $6.19.

ShowHide Related Items >><<
BMY Bristol-Myers
$60.31 /

+ (+0.00%)

ARNA Arena Pharmaceuticals
$65.46 /

+6.76 (+11.52%)

ARNA Arena Pharmaceuticals
$65.46 /

+6.76 (+11.52%)

05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
BMY Bristol-Myers
$60.31 /

+ (+0.00%)

06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BMY Bristol-Myers
$60.31 /

+ (+0.00%)

ARNA Arena Pharmaceuticals
$65.46 /

+6.76 (+11.52%)

BMY Bristol-Myers
$60.31 /

+ (+0.00%)

BMY Bristol-Myers
$60.31 /

+ (+0.00%)

ARNA Arena Pharmaceuticals
$65.46 /

+6.76 (+11.52%)

BMY Bristol-Myers
$60.31 /

+ (+0.00%)

Syndicate
Adaptimmune 20M share Secondary priced at $11.00 » 06:16
06/02/20
06/02
06:16
06/02/20
06:16
ADAP

Adaptimmune

$11.61 /

+0.6 (+5.45%)

The deal size was…

The deal size was increased to 20M shares of common stock from 12.5M shares of common stock. Cowen and SVB Leerink acted as joint book running managers for the offering.

ShowHide Related Items >><<
ADAP Adaptimmune
$11.61 /

+0.6 (+5.45%)

ADAP Adaptimmune
$11.61 /

+0.6 (+5.45%)

06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
05/29/20 Mizuho
Adaptimmune data 'incrementally supportive,' but still early, says Mizuho
ADAP Adaptimmune
$11.61 /

+0.6 (+5.45%)

  • 02
    Jun
ADAP Adaptimmune
$11.61 /

+0.6 (+5.45%)

ADAP Adaptimmune
$11.61 /

+0.6 (+5.45%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.